Latest findings from OKYO Pharma's Phase 2 trial on OK-101 for dry eye disease. Significant reductions in ocular pain, improved Tear Film Break-Up Time, and symptomatic relief were observed. Statistically significant effects pave the way for Phase 3 development.
OKYO Pharma Limited (NASDAQ: OKYO) announced that its first drug candidate, OK-101, presently in a 240-patient phase 2 trial in patients with dry eye disease (DED) is currently showing a positive safety profile in
Gainers Orchard Therapeutics plc (NASDAQ: ORTX) shares climbed 97.7% to $15.98 after the company agreed to be acquired by Japan's Kyowa Kirin for $16.00 per ADS in cash plus an additional contingent value right of $1.00 per ADS.
